Press Releases

  • 10/08/14
    Neos Therapeutics Announces Issuance of Key Patent Covering its Extended Release Oral Disintegrating Tablet (XR-ODT) Platform Technology
  • 09/09/14
    Neos Therapeutics, Inc. Announces Settlement of Pending Patent Litigation Concerning its Amphetamine Polistirex XR-ODT (NT-0202) with Shire LLC
  • 09/08/14
    Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.
  • 07/15/14
    Neos Therapeutics Announces Positive Phase 3 Study Results for its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) in ADHD Patients
  • 05/22/14
    Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer
  • 05/15/14
    Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products: US Patent No. 8,709,491 will Provide Protection Until 2032
  • 04/23/14
    Neos Therapeutics Announces $20 Million Loan Facility and Updated Total of $18 Million for its Additional Series C Financing
  • 03/04/14
    Neos Therapeutics Completes $15.5 Million Additional Series C Financing